This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gruber, A. Articles by Harker, L. A. Search for Related Content PubMed PubMed Citation Articles by Gruber, A. Articles by Harker, L. A.

Circulation, Vol 82, 578-585, Copyright © 1990 by American Heart Association

ARTICLES

Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis

A Gruber, SR Hanson, AB Kelly, BS Yan, N Bang, JH Griffin and LA Harker
Committee on Vascular Biology, Research Institute of Scripps Clinic, La Jolla, CA 92037.

Activated protein C (APC) is an antithrombotic enzyme. The therapeutic potential of infused human recombinant APC (rAPC) was studied in a primate model of platelet-dependent thrombosis. Eight baboons with chronic femoral arteriovenous shunts received rAPC infusions for 1 hour. The shunts were extended with 5-cm long, 4-mm-i.d. thrombogenic Dacron graft segments for the time of infusion. The plasma level of the enzyme, the blood flow in the shunt, and the deposition of indium-111- labeled platelets and iodine-125 fibrinogen on the graft were measured. The influence of rAPC infused at doses of 0.25 and 1.0 mg/kg-hr was compared with the effects of control infusions of saline. Five of eight control grafts occluded within 60 minutes, whereas there was no change in the blood flow during rAPC infusion. Deposition of platelets was inhibited by 13 +/- 10% and by 42 +/- 13% (mean +/- SEM) after 30 minutes of infusion at the two doses, which gave rise to circulating rAPC plasma concentrations of 0.4 and 1.9 mg/l, respectively. Both doses significantly inhibited fibrin deposition in the graft. Circulating plasma markers of thrombus formation and of fibrinolysis did not increase significantly during rAPC infusion; measurements of bleeding time were also within normal limits. Thus, rAPC, like human plasma-derived APC, inhibited thrombus formation without impairing primary hemostasis.

This article has been cited by other articles:

				J. L. Contreras, C. Eckstein, C. A. Smyth, G. Bilbao, M. Vilatoba, S. E. Ringland, C. Young, J. A. Thompson, J. A. Fernandez, J. H. Griffin, et al. Activated Protein C Preserves Functional Islet Mass After Intraportal Transplantation: A Novel Link Between Endothelial Cell Activation, Thrombosis, Inflammation, and Islet Cell Death Diabetes, November 1, 2004; 53(11): 2804 - 2814. [Abstract] [Full Text] [PDF]

				P. Barton, A. C. Kalil, S. Nadel, B. Goldstein, R. Okhuysen-Cawley, R. J. Brilli, J. S. Takano, L. D. Martin, P. Quint, T. S. Yeh, et al. Safety, Pharmacokinetics, and Pharmacodynamics of Drotrecogin Alfa (Activated) in Children With Severe Sepsis Pediatrics, January 1, 2004; 113(1): 7 - 17. [Abstract] [Full Text] [PDF]

				M. Shibata, S. R. Kumar, A. Amar, J. A. Fernandez, F. Hofman, J. H. Griffin, and B. V. Zlokovic Anti-Inflammatory, Antithrombotic, and Neuroprotective Effects of Activated Protein C in a Murine Model of Focal Ischemic Stroke Circulation, April 3, 2001; 103(13): 1799 - 1805. [Abstract] [Full Text] [PDF]

				C. V. Jackson, B. D. Bailey, and T. J. Shetler Pharmacological Profile of Recombinant, Human Activated Protein C (LY203638) in a Canine Model of Coronary Artery Thrombosis J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 967 - 971. [Abstract] [Full Text]

				A. G. Zaman, J. I. Osende, J. H. Chesebro, V. Fuster, A. Padurean, R. Gallo, S. G. Worthley, G. Helft, O. X. Rodriguez, J. T. Fallon, et al. In Vivo Dynamic Real-Time Monitoring and Quantification of Platelet-Thrombus Formation : Use of a Local Isotope Detector Arterioscler Thromb Vasc Biol, March 1, 2000; 20(3): 860 - 865. [Abstract] [Full Text] [PDF]

				S. R. Lentz, J. A. Fernandez, J. H. Griffin, D. J. Piegors, R. A. Erger, M. R. Malinow, and D. D. Heistad Impaired Anticoagulant Response to Infusion of Thrombin in Atherosclerotic Monkeys Associated With Acquired Defects in the Protein C System Arterioscler Thromb Vasc Biol, July 1, 1999; 19(7): 1744 - 1750. [Abstract] [Full Text] [PDF]

				R. F. Macko, L. A. Killewich, J. A. Fernandez, D. K. Cox, A. Gruber, and J. H. Griffin Brain-Specific Protein C Activation During Carotid Artery Occlusion in Humans Stroke, March 1, 1999; 30(3): 542 - 545. [Abstract] [Full Text] [PDF]

				R. M. Camire, M. Kalafatis, P. Simioni, A. Girolami, and P. B. Tracy Platelet-Derived Factor Va/VaLeiden Cofactor Activities Are Sustained on the Surface of Activated Platelets Despite the Presence of Activated Protein C Blood, April 15, 1998; 91(8): 2818 - 2829. [Abstract] [Full Text] [PDF]

				Y. Cadroy, A. Diquelou, D. Dupouy, J.P. Bossavy, K.S. Sakariassen, P. Sie, and B. Boneu The Thrombomodulin/Protein C/Protein S Anticoagulant Pathway Modulates the Thrombogenic Properties of the Normal Resting and Stimulated Endothelium Arterioscler Thromb Vasc Biol, March 1, 1997; 17(3): 520 - 527. [Abstract] [Full Text]

				K. D. Kurz, T. Smith, A. Wilson, B. Gerlitz, M. A. Richardson, and B. W. Grinnell Antithrombotic Efficacy in the Guinea Pig of a Derivative of Human Protein C With Enhanced Activation by Thrombin Blood, January 15, 1997; 89(2): 534 - 540. [Abstract] [Full Text] [PDF]

				M. S. Runge, L. A. Harker, C. Bode, J. Ruef, A. B. Kelly, U. M. Marzec, E. Allen, R. Caban, S.-Y. Shaw, E. Haber, et al. Enhanced Thrombolytic and Antithrombotic Potency of a Fibrin-Targeted Plasminogen Activator in Baboons Circulation, September 15, 1996; 94(6): 1412 - 1422. [Abstract] [Full Text]

				P. K. Shah New Antithrombotic Drugs for Coronary Artery Disease Journal of Cardiovascular Pharmacology and Therapeutics, April 1, 1996; 1(2): 165 - 176. [PDF]

				T. Yokoyama, A. B. Kelly, U. M. Marzec, S. R. Hanson, S. Kunitada, and L. A. Harker Antithrombotic Effects of Orally Active Synthetic Antagonist of Activated Factor X in Nonhuman Primates Circulation, August 1, 1995; 92(3): 485 - 491. [Abstract] [Full Text]

				B. Arnljots and B. Dahlback Antithrombotic Effects of Activated Protein C and Protein S in a Rabbit Model of Microarterial Thrombosis Arterioscler Thromb Vasc Biol, July 1, 1995; 15(7): 937 - 941. [Abstract] [Full Text]

				P. Theroux, F. Perez-Villa, D. Waters, J. Lesperance, F. Shabani, and R. Bonan Randomized Double-Blind Comparison of Two Doses of Hirulog With Heparin as Adjunctive Therapy to Streptokinase to Promote Early Patency of the Infarct-Related Artery in Acute Myocardial Infarction Circulation, April 15, 1995; 91(8): 2132 - 2139. [Abstract] [Full Text]

				A. T. Gentile, T. G. DeLoughery, and J. M. Porter Novel Antithrombotic Agents in Vascular Surgery Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 1994; 7(2): 57 - 72. [PDF]